HK Stock Market Move | SCIENTECH (02291) surges more than 35% in the afternoon, the company will release annual performance at the end of this month, with the core product being a congenital heart disease closure device.

SCIENTECH (02291) soared more than 35% in the afternoon, rising 30.63% to HK$18.55 as of the time of writing, with a turnover of HK$667.227 million. Huayuan Securities has released a research report stating that the number of TAVR surgeries in mainland China is expected to continue to rise from 2010 to 2025, exceeding 18,000 cases in 2025, an 8.1% increase compared to the previous year. The proportion of valve replacement procedures is increasing year by year, with the proportion of TAVR patients receiving valve replacement reaching 7.50% in 2024 and 13% in 2025. Long-term follow-up data for self-expanding and balloon-expandable valves will be released at the end of 2025 and the beginning of 2026, showing differences in durability. Public information shows that among the subsidiaries of Lepu Medical Technology, SCIENTECH focuses on heart valve and occluder products, while Lepu Bio focuses on innovative cancer drugs. SCIENTECH plans to hold a board meeting on March 30th to approve its annual performance. In the first half of 2025, revenue from SCIENTECH's congenital heart disease occluder products was 161 million yuan, accounting for 48.7% of total revenue for the period, with a year-on-year growth of 24.8%, making it the core source of income for SCIENTECH.